Therapeutic targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu®) disables cancer cell survival in human pancreatic cancer with acquired chemoresistance

BACKGROUND: Resistance to drug therapy, along with high rates of metastasis, contributes to the low survival rate in patients diagnosed with pancreatic cancer. An alternate treatment for human pancreatic cancer involving targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu®) was investiga...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Shea, Leah K, Abdulkhalek, Samar, Allison, Stephanie, Neufeld, Ronald J, Szewczuk, Myron R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896323/
https://www.ncbi.nlm.nih.gov/pubmed/24470763
http://dx.doi.org/10.2147/OTT.S55344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896323/
https://www.ncbi.nlm.nih.gov/pubmed/24470763
http://dx.doi.org/10.2147/OTT.S55344

Ejemplares similares